韩文霞

【摘 要】目的：分析吉西他滨联合培门冬酶、顺铂、地塞米松方案治疗晚期结外鼻型NK/T细胞淋巴瘤的临床效果。方法：选取2017年4月至2018年6月于本院收治的50例结外鼻型NK/T细胞淋巴瘤患者为研究对象，将其随机划分为观察组与对照组。对照组采取吉西他滨联合培门冬酶治疗方案，观察组采取吉西他滨联合培门冬酶、顺铂、地塞米松方案，对比两组患者临床治疗效果。结果：观察组患者与对照组患者接受2～6周的化疗，在治疗过程中，观察组死亡2例，死亡率为8.0%。对照组患者死亡6例，死亡率为24.0%。两组患者临床疗效、治疗过程中不良反应率对比，观察组明显优于对照组。两组患者各项指标对比，组间数据差异具有统计学意义（P<0.05）。结论：吉西他滨联合培门冬酶、顺铂、地塞米松方案治疗晚期结外鼻型NK/T细胞淋巴瘤，应用疗效显著，可最大程度减少患者治疗过程中的不良反应与过敏发生率。

【关键词】吉西他滨;培门冬酶;顺铂;地塞米松;联合治疗晚期结外鼻型NK/T细胞淋巴瘤;临床效果

Clinical effect analysis of gemcitabine combined with pembellase， cisplatin and dexamethasone in the treatment of advanced extranodal nasal type NK/T cell lymphoma

Han Wenxia

Fangzi District People's Hospital， Weifang City， Weifang， Shandong 261200

[Abstract] Objective：To analyze the clinical effects of gemcitabine combined with pembellase， cisplatin and dexamethasone in the treatment of advanced extranodal nasal type NK/T cell lymphoma. Methods： Fifty patients with extranodal nasal type NK/T-cell lymphoma admitted to our hospital from April 2008 to June 1818 were enrolled in the study. They were randomly divided into observation group and control group. The control group was treated with gemcitabine combined with Pemetrexase. The observation group was treated with gemcitabine combined with Pemetrex， Cisplatin and Dexamethasone to compare the clinical effects of the two groups. Results： Patients in the observation group and the control group received 2～6 weeks of chemotherapy. During the treatment， 2 patients died in the observation group， and the mortality rate was 8.0%. In the control group， 6 patients died and the mortality rate was 24.0%. The clinical efficacy and adverse reaction rate in the two groups of patients were significantly better than the control group. There were statistically significant differences in data between the two groups （P<0.05）. Conclusion： Gemcitabine combined with Pembellase， Cisplatin and Dexamethasone in the treatment of advanced extranodal nasal type NK/T-cell lymphoma with significant therapeutic effect can minimize the incidence of adverse reactions and allergies during treatment.

[Key words]Gemcitabine; Pemetrexase; Cisplatin; Dexamethasone; Combination therapy for advanced extranodal nasal type NK/T cell lymphoma; Clinical effect

結外鼻型NK/T细胞淋巴瘤本身属于一种侵袭性较强的非霍奇金淋巴瘤，一般常见在亚洲与拉丁美洲，具有病程快的特点，就晚期结外鼻型NK/T细胞淋巴瘤预后效果较差[1]。2016年NCCM指南退出了化疗联合治疗手段，可切实保障结外鼻型NK/T细胞淋巴瘤治疗效果[2]。本文作者主要研究吉西他滨联合培门冬酶、顺铂、地塞米松方案治疗晚期结外鼻型NK/T细胞淋巴瘤的临床效果，详细报道如下。

1 资料与方法

1.1 临床资料

选取2017年4月至2018年6月于本院收治的50例结外鼻型NK/T细胞淋巴瘤患者为研究对象，在争得患者及其家属同意后，填写问卷调查资料。将50例患者随机分为对照组与观察组，每组各25例患者。……